TABLE 3.
MIC distributions of Candida species other than C. albicans and C. glabrataa
| Species | Sample type | n | FLC |
VRC |
ANI |
MICA |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC range (mg/liter) | MIC50 (mg/liter) | No. (%) of resistant isolatesb | MIC range (mg/liter) | MIC50 (mg/liter) | MIC range (mg/liter) | MIC50 (mg/liter) | No. (%) of resistant isolatesb | Range (mg/liter) | MIC50 (mg/liter) | |||
| C. dubliniensis | Blood | 3 | ≤0.125–1 | NA | 0 | ≤0.03 | NA | 0.015–0.03 | NA | NA | ≤0.008–0.015 | NA |
| Swab | 8 | ≤0.125–≥128 | NA | 1c (12.5) | ≤0.03–>4 | NA | 0.015–0.06 | NA | NA | ≤0.008–0.06 | NA | |
| C. tropicalis | Blood | 8 | ≤0.125–16 | NA | 1d (12.5) | ≤0.03–4 | NA | ≤0.008–0.06 | NA | 0 | ≤0.008–0.03 | NA |
| Swab | 12 | 0.25–≥128 | 0.5 | 2e (16.7) | ≤0.03–>4 | ≤0.03 | ≤0.008–0.06 | 0.03 | 0 | ≤0.008–0.03 | 0.015 | |
| C. krusei | Blood | 8 | 16–≥128 | NA | Intrinsic | 0.125–2 | NA | 0.015–0.125 | NA | 2 (25)g | 0.06–0.125 | NA |
| Swab | 11 | 16–≥128 | 32 | Intrinsic | 0.125–2 | 0.25 | 0.03–0.125 | 0.06 | 2 (18.2)g | 0.06–0.25 | 0.125 | |
| S. cerevisiae | Blood | 2 | 16 | NA | NA | 0.25–0.5 | NA | 0.06–0.25 | NA | NA | 0.125 | NA |
| Swab | 12 | 2–16 | 4 | NA | 0.06–0.25 | 0.125 | 0.03–0.5 | 0.125 | NA | 0.06–0.25 | 0.125 | |
| C. parapsilosis | Blood | 10 | 0.25–1 | 0.5 | 0 | ≤0.03 | ≤0.03 | 0.5–>1 | 1 | NA | 0.5–>1 | 1 |
| Swab | 3 | 0.5–8 | NA | 1f (33.3) | ≤0.03–0.125 | NA | 1–>1 | NA | NA | 0.5–>1 | NA | |
FLC, fluconazole; VRC, voriconazole; ANI, anidulafungin; MICA, micafungin; NA, not applicable (too few isolates).
Only applicable if a breakpoint exists (EUCAST breakpoints were used).
One additional isolate was FLC intermediate, with a MIC of 4 mg/liter. Both patients with these isolates were exposed to fluconazole for >14 days.
Trailing phenotype (50% growth inhibition in entire FLC MIC range) and no information on prophylactic treatment for this patient.
Trailing phenotype. Both patients received caspofungin monotherapy (>14 days). One patient had a genetically similar and susceptible C. tropicalis isolate in blood.
A C. parapsilosis isolate with an FLC MIC of 8 mg/liter was found in a patient exposed to fluconazole for >14 days.
C. krusei isolates harboring the Fks1 L701M substitution were obtained from 2 persistently colonized patients (same species and genotype in the blood and swab), one treated with caspofungin for >14 days and the other exposed to the following three drugs for >7 days: fluconazole, voriconazole, and amphotericin B.